SELENOP-LRP8-mediated macrophage-endothelial cell interaction promotes breast cancer vascular invasion by inducing metabolic reprogramming in endothelial cells
Jul 2026· Cellular and Molecular Life Sciences· 0 citations
TL;DR
Findings identify a SELENOP + macrophage-endothelial metabolic axis associated with breast cancer VI and support further investigation of combined anti-angiogenic and cholesterol-pathway-directed strategies in preclinical models.
Abstract
Vascular invasion (VI) is an early event in breast cancer dissemination. However, the mechanisms by which macrophages and endothelial cells cooperate to drive this process remain incompletely understood. We aimed to identify macrophage subsets associated with VI and determine how they influence endothelial cell behavior.
Single-cell RNA sequencing and spatial transcriptomic profiling and were conducted on breast cancer specimens partitioned by their vascular invasion characteristics. Multiplex immunofluorescence, coculture assays, transcriptomic, proteomic, and metabolomic profiling, molecular docking, and co-immunoprecipitation were used to characterize the SELENOP-LRP8 axis. In vivo validation was conducted using a myeloid-specific
Selenop
knockout model (
Selenop
f/f
;
Lyz2
Cre
) bearing E0771 allografts and treated with bevacizumab and/or Ebronucimab.
A distinct SELENOP
+
macrophage subset was enriched in VI-positive breast tumors and exhibited close spatial proximity to endothelial cells. In vitro, macrophage-derived SELENOP enhanced endothelial migration and tube formation. Multi-omics analyses suggested that SELENOP binds endothelial LRP8, leading to cholesterol metabolic rewiring and Hedgehog pathway activation. In the mouse model,
Selenop
deficiency reduced tumor growth and vascularization, while combination treatment with bevacizumab and Ebronucimab produced the strongest inhibitory effect among the treatment groups.
These findings identify a SELENOP
+
macrophage-endothelial metabolic axis associated with breast cancer VI and support further investigation of combined anti-angiogenic and cholesterol-pathway-directed strategies in preclinical models.
The transcriptomic and cell–cell communication changes observed are consistent with the establishment of a more immune-permissive tumor microenvironment, supporting the potential of BET degradation as a strategy to complement immunotherapy and improve therapeutic responsiveness in breast cancer.
Deeksha Sharma, Cody G. Hager, Max S. Wicha et al.· Breast Cancer· 0 citations
The results suggest that RAMP3 contributed to the establishment of an immunosuppressive TME and integration with human clinical datasets supports further investigation of RAMP3 as a potential therapeutic target for overcoming resistance to immune checkpoint therapy in breast cancer.
Yan Zhang, Megumu Tanaka, Takayuki Sakurai et al.· Journal of Translational Med...· 0 citations
A spatially organized POSTN⁺ CAF–SPP1⁺ macrophage niche that may contribute to stromal remodeling, CD8⁺ T-cell exclusion, and potentially reduced immunotherapy benefit in LUAD is defined.
Ankang Zhu, Jian-Yuan Huang, Juan Zhang et al.· Journal of Translational Med...· 0 citations
WNK4 acts as an immune-relevant suppressor in endometrial cancer, partly by limiting M2-like polarization and weakening macrophage-driven tumor support, partly by limiting M2-like polarization and weakening macrophage-driven tumor support.
This study uncovered previously unrecognized immunosuppressive cell populations and key immune regulators that advance understanding of CRC immune evasion and highlight potential targets for personalized immunotherapy.
Dominika Miroszewska, Shi-Yang Song, Víctor Urbiola-Salvador et al.· British Journal of Cancer· 0 citations
The findings reveal a new regulatory mechanism that drives the spread of colorectal cancer to the liver and suggest potential targets for future therapies to prevent metastasis.
Han Yang, Jin-Hao Yu, Dong Hou et al.· Cancers· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.